Dear Ms. Cress:

Please refer to your supplemental new drug application (sNDA) dated and received November 23, 2021, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Retevmo (selpercatinib) capsules.

This Prior Approval sNDA provides for conversion from accelerated to regular approval of Retevmo capsules for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test.

**APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

**WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS**

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information.
CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Patient Package Insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

SUBPART H Fulfilled

We approved this NDA under the regulations at 21 CFR 314 Subpart H for accelerated approval of new drugs for serious or life-threatening illnesses. Approval of this supplement fulfills your commitments made under 21 CFR 314.510 with respect to the indication for the treatment of patients with metastatic RET fusion-positive NSCLC. We refer to the original approval letter regarding outstanding requirements under 21 CFR 314.510 with respect to other approved indications.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database [https://www.fda.gov/RegulatoryInformation/Guidances/default.htm](https://www.fda.gov/RegulatoryInformation/Guidances/default.htm)

U.S. Food and Drug Administration
Silver Spring, MD 20993
[www.fda.gov](http://www.fda.gov)
Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.

FULFILLMENT OF POSTMARKETING REQUIREMENTS/COMMITMENTS

We have received your submission dated November 23, 2021, containing the final reports for the following postmarketing requirements (3829-2 and 3829-9), and your September 29, 2021, submission reporting on the following postmarketing commitments (3829-10 and 3829-11), listed in the May 8, 2020, approval letter.

3829-2 Submit a final report including datasets from an ongoing clinical trial to verify and further characterize the clinical benefit of selpercatinib for the treatment of patients with 1) treatment-naïve RET fusion-positive NSCLC and with 2) RET fusion-positive NSCLC who have previously received platinum chemotherapy that will provide a more precise estimation of the BICR-assessed overall response rate and duration of response after all responders in the population of at least 65 patients have been followed for at least 12 months from the date of initial response (or until disease progression, whichever comes first) in patients with treatment-naïve NSCLC and after all responders have been followed for at least 6 months in the population of patients (at least 180 patients) with NSCLC previously treated with platinum therapy.

3829-9 Submit the final report and datasets from a clinical drug-drug interaction study to evaluate the effect of selpercatinib on the pharmacokinetics of a P-gp substrate, and inform appropriate management strategies for clinically relevant drug interactions. Design and conduct the trial in accordance with the FDA Guidance for Industry titled: “Clinical Drug Interaction Studies - Cytochrome P450 Enzyme and Transporter-Mediated Drug Interactions.”

3829-10 Submit the final report of an analytical and clinical validation study, using clinical trial data, that is adequate to support labeling of an in vitro diagnostic device that demonstrates the device is essential to the safe and effective use of selpercatinib for patients with RET gene fusions in non-small cell lung cancer. The results of the validation study may inform product labeling.

3829-11 Submit the final report of an analytical and clinical validation study, using clinical trial data, that is adequate to support labeling of an in vitro diagnostic device that demonstrates the device is essential to the safe and effective use of selpercatinib for patients with RET gene fusion-positive thyroid cancer and RET mutation-positive medullary thyroid cancer. The results of the validation study may inform product labeling.

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov

Reference ID: 5048871
We have reviewed your submissions and conclude that the above requirements and commitments were fulfilled.

We remind you that there are postmarketing requirements listed in the May 8, 2020, approval letter that are still open.

POSTMARKETING REQUIREMENTS UNDER 505(o)

Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act (FDCA) authorizes FDA to require holders of approved drug and biological product applications to conduct postmarketing studies and clinical trials for certain purposes, if FDA makes certain findings required by the statute.

We have determined that an analysis of spontaneous postmarketing adverse events reported under subsection 505(k)(1) of the FDCA will not be sufficient to assess a signal of a serious risk of selpercatinib with BCRP substrates.

Furthermore, the active postmarket risk identification and analysis system as available under section 505(k)(3) of the FDCA will not be sufficient to assess this serious risk.

Finally, we have determined that only a clinical trial (rather than a nonclinical or observational study) will be sufficient to assess a signal of a serious risk.

Therefore, based on appropriate scientific data, FDA has determined that you are required to conduct the following trials:

4335-1  Conduct a clinical drug-drug interaction study to evaluate the effect of selpercatinib on the pharmacokinetics of a BCRP substrate and inform appropriate management strategies for clinically relevant drug interactions. Design and conduct the trial in accordance with the FDA Guidance for Industry titled: “Clinical Drug Interaction Studies - Cytochrome P450 Enzyme and Transporter- Mediated Drug Interactions.”

The timetable you submitted on August 31, 2022, states that you will conduct this trial according to the following schedule:

Draft Protocol Submission: 01/2023
Final Protocol Submission: 04/2023
Study Completion: 02/2024
Final Report Submission: 07/2024

Submit the datasets with the final report submission.
FDA considers the term final to mean that the applicant has submitted a protocol, the FDA review team has sent comments to the applicant, and the protocol has been revised as needed to meet the goal of the study or clinical trial.\(^3\)

Submit clinical protocol(s) to your IND 133193 with a cross-reference letter to this NDA. Submit nonclinical and chemistry, manufacturing, and controls protocols and all final report(s) to your NDA. Prominently identify the submission with the following wording in bold capital letters at the top of the first page of the submission, as appropriate: **Required Postmarketing Protocol Under 505(o), Required Postmarketing Final Report Under 505(o), Required Postmarketing Correspondence Under 505(o).**

Section 505(o)(3)(E)(ii) of the FDCA requires you to report periodically on the status of any study or clinical trial required under this section. This section also requires you to periodically report to FDA on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Section 506B of the FDCA, as well as 21 CFR 314.81(b)(2)(vii) requires you to report annually on the status of any postmarketing commitments or required studies or clinical trials.

FDA will consider the submission of your annual report under section 506B and 21 CFR 314.81(b)(2)(vii) to satisfy the periodic reporting requirement under section 505(o)(3)(E)(ii) provided that you include the elements listed in 505(o) and 21 CFR 314.81(b)(2)(vii). We remind you that to comply with 505(o), your annual report must also include a report on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Failure to submit an annual report for studies or clinical trials required under 505(o) on the date required will be considered a violation of FDCA section 505(o)(3)(E)(ii) and could result in enforcement action.

**PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry **Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs.**\(^4\)

---


\(^4\) For the most recent version of a guidance, check the FDA guidance web page at [https://www.fda.gov/media/128163/download](https://www.fda.gov/media/128163/download).

U.S. Food and Drug Administration
Silver Spring, MD 20993
[www.fda.gov](http://www.fda.gov)
You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov. Information and Instructions for completing the form can be found at FDA.gov.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety-related information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety-related information that appears in the revised labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4).

**PATENT LISTING REQUIREMENTS**

Pursuant to 21 CFR 314.53(d)(2) and 314.70(f), certain changes to an approved NDA submitted in a supplement require you to submit patent information for listing in the Orange Book upon approval of the supplement. You must submit the patent information required by 21 CFR 314.53(d)(2)(i)(A) through (C) and 314.53(d)(2)(ii)(A) and (C), as applicable, to FDA on Form FDA 3542 within 30 days after the date of approval of the supplement for the patent information to be timely filed (see 21 CFR 314.53(c)(2)(ii)). You also must ensure that any changes to your approved NDA that require the submission of a request to remove patent information from the Orange Book are submitted to FDA at the time of approval of the supplement pursuant to 21 CFR 314.53(d)(2)(ii)(B) and 314.53(f)(2)(iv).

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Maritsa Stephenson, Regulatory Health Project Manager, at 301-796-1760.

---

5 [http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf](http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf)


U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
Sincerely,

{See appended electronic signature page}

Harpreet Singh, M.D.
Director
Division of Oncology 2 (DO 2)
Office of Oncologic Diseases (OOD)
Center for Drug Evaluation and Research

ENCLOSURE(S):
• Content of Labeling
  o Prescribing Information
  o Patient Package Insert
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

ERIN A LARKINS
09/21/2022 12:52:29 PM
As designated signatory authority for Dr. Harpreet Singh